Physician profile
Maud Ward
NPI 1609822709
$6,081.38
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,963 · 2020: $886 · 2021: $1,624 · 2022: $1,272 · 2023: $113 · 2024: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,230.60 | 2019-2022 | |
| Novo Nordisk INC | $555.63 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $491.34 | 2019-2021 | |
| Lilly USA, LLC | $436.89 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $353.03 | 2019-2022 | |
| Vifor Pharma, INC. | $350.91 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $311.22 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $303.22 | 2019-2022 | |
| Abbvie INC. | $272.45 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.58 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $191.26 | 2019-2021 | |
| Allergan, INC. | $161.51 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $151.00 | 2022 | |
| Merck Sharp & Dohme LLC | $129.74 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $125.00 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $119.16 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $116.19 | 2020-2022 | |
| Lexicon Pharmaceuticals, INC. | $112.63 | 2023 | Inpefa |
| Phathom Pharmaceuticals, INC. | $97.84 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $95.46 | 2021 | |
| Amarin Pharma, INC. | $57.47 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.58 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $28.88 | 2021 | |
| Astellas Pharma US INC | $24.81 | 2020 | |
| Scilex Pharmaceuticals INC. | $21.57 | 2020 | |
| Bausch Health US, LLC | $18.25 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.19 | 2022 | |
| Seqirus USA INC | $15.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maud Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.